Top Markets
Coin of the day
Aroa Biosurgery Limited Aroa Biosurgery Limited

Aroa Biosurgery Limited

ARX
Kedudukan dalam Saham #20200
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated... Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
Harga Saham
$0.39848591
Modal Pasaran
$137.67M
Perubahan (1 hari)
-1.74%
Perubahan (1 tahun)
-3.96%
Negara
NZ
Perdagangan Aroa Biosurgery Limited (ARX)

Kategori

Pendapatan untuk Aroa Biosurgery Limited (ARX)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Aroa Biosurgery Limited, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Aroa Biosurgery Limited dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
- -
DE